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Mechanism of furosemide resistance in analbuminemic rats and
hypoalbuminemic patients. To elucidate the mechanism of resistance of
hypoalbuminemic patients to furosemide, the effect of this diuretic on
urine volume of normal and analbuminemic rats (NAR) and of hypoal-
buminemic patients was studied. Intravenous administration of furose
mide rapidly enhanced sodium diuresis in normal rats but not in NAR.
Total plasma clearance and distribution volume of furosemide were
much larger in NAR than in normal rats, while no significant difference
in these pharmacokinetic parameters was observed for the unbound
fraction of the diuretic between the two animal groups. In contrast,
urinary secretion of furosemide was significantly lower in NAR than in
normal rats. Injected furosemide bound to albumin markedly promoted
diuresis in NAR, while the same dose of albumin alone had no effect,
indicating that binding to albumin is essential for the delivery of
furosemide to the kidney, the site for its action. Injection of the
complex rapidly increased the urine volume of hypoalbuminemic pa-
tients who showed a marked resistance to this diuretic. Thus, the
resistance to furosemide in both NAR and hypoalbuminemic patients
may be explained on the same basis.
Edema is frequently associated with hypoalbuminemia
caused by various diseases, such as nephrotic syndrome, cir-
rhosis and neoplasm. Furosemide is commonly used to treat
patients with severe fluid retention, and induces diuresis pre-
dominantly by blocking the luminal reabsorption of sodium and
chloride in renal tubules [I]. Resistance to diuretics, including
furosemide, is frequently encountered in patients with severe
hypoalbuminemia [2, 3] but the mechanism of resistance is not
known.
Many hydrophobic organic anions, such as bilirubin, bile
acids, fatty acids, sulfobromophthalein (BSP), and phenolsul-
fophthalein (PSP), circulate by being bound to plasma albumin.
Previous studies using mutant analbuminemic rats (NAR) re-
vealed that binding of these amphipathic organic anions with
circulating albumin is important for vectorial transport of these
ligands to liver and kidney [4—7]. Furosemide is an organic
anion that binds strongly to albumin [8, 9]. This drug is known
to undergo transtubular secretion at proximal tubules via the
transport system for amphipathic organic anions [10]. Thus, the
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resistance of hypoalbuminemic patients to furosemide may
possibly result from an impaired delivery of this diuretic to the
renal peritubular space because of a deficiency in albumin. In
support of this view, a preliminary experiment showed that
NAR exhibited a marked resistance to furosemide.
The present work reveals that intravenous injection of furo-
semide bound to albumin caused a remarkable diuresis in NAR
otherwise resistant to this drug. Based on this finding, effective
diuresis was achieved by infusion of the albumin—furosemide
complex in hypoalbuminemic human subjects who were resist-
ant to the diuretic.
Methods
Furosemide and rat albumin (fraction V) were purchased
from Sigma Chemical Co. (St. Louis, Missouri, USA). Human
albumin (25% solution) and 1% solution of furosemide (Lasix)
were obtained from Chemo-Sero Research Institute (Kuma-
moto, Japan) and Hoechst—Japan (Tokyo, Japan), respectively.
Other reagents used were of analytical grade.
Animals were fed laboratory chow and water ad libitum and
were used for experiments without fasting. Unless otherwise
stated, experiments with animals in vivo were performed be-
tween 9:00 a.m. and 12:00 noon under pentobarbital anesthesia
(50 mg/kg). During experiments, the body temperature of
pentobarbital treated rats was kept constant at 37°C by using
tungsten lamp. Urine samples were collected from unartesthe-
tized rats in a metabolism cage over a period of one hour. Urine
samples were also obtained from anesthetized animals for the
consecutive 10 minute collection periods by urinary bladder
cannulation before and after administration of drugs. Intrave-
nous administration of 0.5 ml saline solution containing furose-
mide and other reagents was performed over a period of 10
seconds.
Urine samples were also obtained from hypoalbuminemic
patients for the consecutive one—hour collection periods by
urinary bladder cannulation before and after the administration
of drugs. In general, patients were given furosemide (20 to 60
mg) with 25 ml of saline solution intravenously between 9:00
a.m. and 10:00 a.m., over a period of 10 minutes. Patients who
were resistant to furosemide were again given the diuretic,
albumin or albumin furosemide complex between 4:00 p.m. and
6:00 p.m. of the day. Furosemide was mixed with albumin
solution to make an equimolar mixture 10 minutes before the
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Fig. 1. Effect offurosemide on urine volume of NAR and normal rats,
Under pentharbital anesthesia, animals were administered furosemide
intravenously (0.5 mg/kg body wt) over a period of 10 seconds. Urine
samples were collected by urinary bladder cannulation for the consec-
utive 10 minute collection period. Arrow (F) indicates the time of
furosemide administration. Other conditions were as described under
the text. A typical result of six experiments. A, NAR; B, normal rats.
Results
Resistance of NAR to .furosemide
Figure 1 shows the effect of furosemide on urine volume in
normal and analbuminemic rats. The rate of urine formation
was markedly increased by a single dose of furosemide in
normal rats and continued for more than 50 minutes. The same
Dose of administered furosemide, mg/kg
Fig. 2. Dose dependent response of natriuresis in NAR and normal
rats. After intramuscular injection of furosemide, urine samples were
collected in a metabolism cage for one hour. Each point represents
mean SD derived from six animals. Symbols are (0) normal rats; (•)
NAR. /
0 300 600
Urinary furosemide excretion, tag/kg/hr
Fig. 3. Sensitivity of the kidney tofurosemide in NAR and normal rats.
After intramuscular administration of variouS dose of furosemide, urine
samples were collected in a metabolism cage. Urine volume and sodium
excretion over a period of one hour after administration of furosemide
were plotted against the amount of furosemide found in the urine.
Symbols are: (0) normal rats; (•) NAR.
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administration. Clinical diagnosis and other conditions of pa-
tients with marked hypoalbuminemia are described in the
Results.
Furosemide concentrations in urine and plasma were deter-
mined by using high—performance liquid chromatography ac-
cording to Hammarlund and Paalzow [11] in a Hitachi 655
Liquid Chromatograph equipped with a column of ODS-
Hypersil C18, 5 t.tm (Shandon). The mobile phase consisted of
40% acetonitrile in 20 m phosphate buffer, pH 2.5. Urinary
concentrations of Na were determined by an ion—selective
electrode (Technicon-SMAC). Binding of furosemide to plasma
proteins was determined by an ultrafiltration method as de-
scribed previously [12].
dose of furosemide failed to enhance diuresis in NAR. To
elucidate the mechanism for furosemide resistance in NAR, the
natriuretic response was compared between the two animal
groups at different furosemide concentrations. Both urine vol-
ume and sodium excretion increased in normal rats with the
increase in the dose of furosemide (Fig. 2). Furosemide induced
increase in urine volume and sodium excretion was much less
pronounced in NAR than in normal rats. When urine volume
and sodium excretion were plotted as a function of the urinary
level of furosemide after administration of various doses of this
diuretic, no significant difference was observed between NAR
and normal rats (Fig. 3), indicating that the renal sensitivity to
furosemide is identical and the same mechanism of natriuresis is
operating in the two animal groups. However, a noticeable
finding elicited from this series of experiments was that the
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Dose of administered furosemide, mg/kg
Fig. 4. Urinary recovery offurosemide in NAR and normal rats. After
intramuscular administration of various dose of furosemide, the amount
of the diuretic excreted in urine within one hour was determined. Each
point represents mean SD derived from six animals. Symbols are (0)
normal rats; (•) NAR.
Time. mm
Fig. 5. Plasma clearance of furosemide in NAR and normal rats.
Under pentobarbital anesthesia, animals were intravenously injected
with furosemide (2 mglkg) with (closed squares) or without equimolar
albumin (circles) in the right femoral vein. At indicated times, blood
samples (0.1 ml) were withdrawn from the left femoral vein and
centrifuged at 13,000 x g for one minute in a Kubota microcentrifuge.
Plasma samples thus obtained were determined for amounts of furose-
mide as described in the text. Symbols are: (0) normal rats; (•, U)NAR.
Parameters
Normal
rats NAR
NAR +
albumin
In vitro protein binding 98.9% 12.0% —
20 furosemide/mI plasma
Plasma clearance
total furosemide mI/mm x kg 9.4 24.4 13.3
unbound fraction liter/mm x kg 0.65 0.67 0.64
Distribution volume
total furosemide ml/kg 59.6 545.5 121.2
unbound fraction 1/kg 4.7 5.1 5.3
Urinary recovery % dose 26 7 18
Details of experimental procedures were as described in Figure 5.
Binding of furosemide to plasma proteins was determined as described
previously [13]. Plasma clearance and distribution volume were calcu-
lated for the total (free form + protein—bound) and the unbound
fraction of furosemide as described previously [6]. Urinary secretion of
the injected furosemide was determined for the urine samples collected
for 30 minutes after the administration.
urinary recovery of furosemide was about three times lower in
NAR than in normal rats irrespective of the dose of the diuretic
(Fig. 4). Thus, the resistance of NAR to furosemide appeared to
result from an impaired accumulation of this diuretic in the
kidney.
Pharmacokinetic analysis of furosemide in NAR
and normal rats
Plasma clearance of intravenously administered furosemide
was compared between NR and normal rats. The intravenously
administered furosemide disappeared from the circulation much
faster in NAR than in normal rats (Fig. 5). Both total plasma
clearance and distribution volume of furosemide (free +
protein—bound) were significantly larger in NAR than in normal
rats (Table 1). However, urinary recovery of furosemide was
markedly lower in NAR than in normal rats. Thus, a significant
amount of furosemide injected to NAR underwent random
distribution to extrarenal tissues presumably due to insufficient
binding of the ligand to plasma protein(s). Although total
plasma clearance and distribution volume of furosemide (free +
protein—bound) was larger in NAR than in normal rats, no
significant difference in the two parameters for the unbound
furosemide was observed between the two animal groups.
Administration of furosemide with an equimolar amount of
albumin markedly decreased the rate of disappearance of the
diuretic from the circulation. Thus, when furosemide was
injected bound to albumin, total plasma clearance and distribu-
tion volume of furosemide were markedly decreased in NAR
while those for the unbound ligand remained unchanged. When
furosemide was intravenously injected bound to albumin, the
urine volume of NAR increased rapidly to reach a maximum at
10 mm after administration (Fig. 6). Urinary excretion of
furoseniide was also greater in NAR when the diuretic was
injected bound to albumin than when the ligand alone was
administered. A single dosage of furosemide (Fig. 1) or albumin
alone (Fig. 6) did not promote diuresis in NAR. These results
indicate that binding of furosemide to circulating albumin may
be important for an efficient delivery of this drug to the kidney,
the site for its diuretic action.
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Table 1. Pharmacokinetic parameters of furosemide in normal
and analbuminemic rats
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Fig. 6. Effect of furosemide—albumin complex on urine volume of
NAR. Under pentobarbital anesthesia, NAR were intravenously in-
jected with furosemide (0.5 mg/kg) mixed with equimolar albumin.
Urine samples were collected as described in Figure I. A, albumin (0. I
glkg); AF, albumin—furosemide complex. Data show a typical result of
five experiments.
Diuresis by furosemide—albumin complex in
furosemide—resistant hypoalbuminemic patients
The finding with NAR suggested that the furosemide—albumin
complex might also promote diuresis in furosemide—resistant
hypoalbuminemic patients. Thus, we tested this on 20 patients
who showed a marked resistance to this diuretic. Figure 7
shows the diuretic response of several hypoalbuminemic pa-
tients to a single dose of furosemide or the furosemide—albumin
complex. Administration of a therapeutic dose of furosemide as
an admixture with equimolar albumin increased the rate of urine
formation in these patients. The same dose of either furosemide
(Fig. 7) or albumin (data not shown) alone failed to promote
diuresis in these patients. The diuretic response was maximal
one hour after administration and decreased thereafter. HPLC
analysis revealed that about 7 to 12% of the injected dose was
excreted in the patients urine within three hours after the
administration of furosemide. Administration of furosemide
with equimolar albumin increased the urinary recovery of the
diuretic to about 24 to 30%. Thus, administration of furo-
semide—albumin complex efficiently promoted diuresis by in-
creasing the urinary recovery of the diuretic in both NAR and
0
—1 0 1 2 3
Time, hr
Fig. 7. Effect of furosemide—albumin complex on urine volume of
hypoalbuminemic human subjects. Hypoalbuminemic and furosemide
resistant patients were intravenously administered 30 mg of furosemide
alone or the diuretic bound to albumin (6 g) over a period of 10 minutes.
Before and after administration of furosemide alone (F) or the
furosemide—albumin complex (AF), urine samples were collected by
uretheral catheterization for the consecutive one hour collection peri-
ods. Plasma albumin levels were 1.0 g/dl (0, cholangiocarcinoma), 2.2
g/dl (X, chronic renal failure), 2.2 g/dl (, pulmonary edema), and 1.9
g/dl (U, brain tumor).
hypoalbuminemic patients. Table 2 summarizes the diuretic
effect of furosemide and the furosemide—albumin complex on
additional hypoalbuminemic patients who showed a marked
resistance to furosemide. Most of these patients showed a
marked increase in the rate of urine formation. The diuretic
response of hypoalbuminemic patients to furosemide and its
albumin complex thus mimiced that of analbuminemic rats.
Discussion
Analbuminemic mutant rats showed a marked "resistance"
to furosemide. Intravenous administration of the furosemide—
albumin complex, but not furosemide alone, markedly in-
creased the rate of urine formation in NAR. These findings
motivated us to test the effect of furosemide-albumin complex
in hypoalbuminemic patients who showed a marked "resist-
ance" to the diuretic. The present work reveals that the
furosemide—albumin complex is also effective in promoting
diuresis in the hypoalbuminemic patients who showed a marked
"resistance" to the diuretic. Previous studies [6] revealed that
the renal transtubular secretion of PSP, an amphipathic organic
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Table 2. Effect of furosemide and furosemide—albumin complex on
urine volume of hypoalbuminemic patients
Patient/age/sex!
Plasma protein Urine volumea mi/hr
Albumin/total Furosemide Furosemide
diagnosis g/dl plasma alone + albumin
S.F. /74/f/chronic renal 1.6/5.3 24b 55b
failure
F.N)/52/rn/liver cirrhosis 3.2/5.4 267b 3975
Y.Y. /74/m/brain hemorrage 2.2/5.2 I 10b 222b
T.T. /88/f/lung cancer 1.7/5.2 58b 178b
S.H. /37/f/amyloidosis 2.1/5.0 120' 260b
F.N.1/52/m/liver cirrhosis 3.2/5.4 330C 467b
l.K.2/70/in/chronic renal 2.3/5.0 60 305
failure
I,K.2/70/rn/chronic renal 2.2/4.8 25C 135c
failure
K.S.3/47/f/cholangio- 1.0/4.7 5ØC l3O
carcinoma
K.S.3/47/f/cholangio- 2.0/4.9 5ØC I 28C
carcinoma
G.M. /81/rn/brain tumor 1.9/4.4 50d lOOC
5K. /78/rn/pulmonary 2.2/4.6 25 IOOC
edema
F.N. /65/rn/liver cirrhosis 1.5/4.3 183d 291d
O,T. /48/f/ovalian cancer 2.7/7.0 61d 150d
S.Y. /73/rn/Japanese 3.5/6.5 oe 0b
encepharitis
K.K. /77/rn/malignant 2.4/5.4 0d 5b
lymphoma
One to three experiments were performed with the same patients at
different days. A different dose of furosemide (20b, 30c, 40d, and 60
mg/patient) was intravenously administered with or without equimolar
albumin.
anion that binds to albumin with high affinity, is lower in NAR
than in normal rats due to random distribution of the ligand to
extrarenal tissues in NAR. Administration of PSP with equimo-
lar albumin resulted in marked increase in the urinary secretion
of the dye, suggesting that binding to circulating albumin may
enhance the vectorial transport of ligand from plasma into urine
by preventing random distribution of PSP among extrarenal
tissues. This argument would hold true for the present finding
that the administration of furosemide with equimolar albumin
increased the urinary excretion of this diuretic in NAR (Table
1). Since NAR shows no remarkable pathology and retains
normal function of liver and kidney [131, the resistance to
furosemide could be primarily explained by the decreased
accumulation of the drug in the kidney, the site for its diuretic
action. Pretreatment of NAR with the same dose of albumin as
that used in the experiments in Figure 6 did not increase the rate
of urine formation. Assuming 36 mI/kg of body weight for the
plasma volume of NAR, an initial concentration of the circu-
lating albumin would be about 0.04 mrvt immediately after
intravenous administration of 0.1 g of albumin per kg of body
weight. Since a large fraction of furosemide remains unbound at
this concentration of plasma albumin [81, it is not surprising that
pretreatment of NAR with such a small dose of albumin did not
elicit the diuretic action of furosemide. Similarly, treatment of
the furosemide—resistant patients with a small dose of albumin
had no effect on the diuretic response to furosemide. The
unbound fraction of furosemide markedly increases when
plasma albumin level is lower than 2 g/dl [9]. Assuming the
plasma volume of 3 1/60 kg of body weight, administration of 4
to 6 g albumin increased the plasma concentration only by 0.13
to 0.2 g/dl. Such a small increase in plasma albumin leyel did not
significantly contribute to the protein binding of the injected
furosemide. High concentration of both a ligand and its binding
protein favor the complex formation. Thus, when injected
bound to albumin, a large fraction of furosemide circulates
bound to albumin for a short period after the administration in
NAR and hypoalbuminemic human subjects. During the initial
passage through the kidney, a significant fraction of albumin—
associated furosemide would be taken up by renal tubular cells
and secreted into the luminal compartment to exhibit its diuretic
action.
Although administration of furosemide—albumin complex sig-
nificantly decreased the total plasma clearance and distribution
volume of furosemide in NAR (Table 1 and Fig. 5), they did not
return to the values in normal rats. Albumin samples used in the
present experiments were the fraction V of rat albumin, which
are known to retain a significant amount of free fatty acids [15].
It has been known that free fatty acids and other amphipathic
anions, such as furosemide, compete the binding site onalbu-
mm and the binding capacity of the fraction V albumin for these
anionic ligands is lower than that of the defatted albumin [12]
and albumin in non-heparinized plasma [II]. Preliminary exper-
iments in NAR revealed that the rate of furosemicle disappear-
ance was slower when the diuretic was injected with defatted
albumin than with fraction V albumin. Furthermore, the furo-
semide—albumin complex was diluted about 20-fold immedi-
ately after its administration, which might affect he equilibrium
binding of the ligand and increase the unbound fraction of the
diuretic. These factors might explain, at least in part, why the
pharmacokinetic parameters in NAR did not return to thpse in
normal rats even if furosemide was injected bound to albumin.
That the diuretic action of the complex in NAR was transient
and its duration was shorter than that of furosemide in normal
animals is consistent with this notion.
The furosemide—albumin complex effectively increased the
urine volume in 14 of 16 hypoalbuminemic patients but did not
promote diuresis in two hypoalbuminemic subjects (S.Y. and
K.K. in Table 2). Renal function and general health of both
patients were very poor; blood pressure was 40 to 60 mm Hg
and anuria continued for two to three days before treatment
with the complex. Thus, the furosemide—albumin complex
appears to exhibit a desired therapeutic effect in hypoalbumin-
ernie patients whose general conditions and renal transport
functions still bring the diuretic in sufficient amounts to the site
of its action and to respond to its diuretic action.
Although the efficient diuresis induced by furosemide—albu-
mm complex in NAR and hypoalbuminemic patients could be
explained on the similar basis as described above, the present
experiments in hypoalbuminemic patients are rather prelimi-
nary. More detailed studies in human subjects should be
performed under well controlled experimental conditions to
understand the full scope of the mechanism for furosemide
resistance in hypoalbuminemic patients.
Huge amounts of human albumin have frequently been used
for therapeutic purposes to complement the decreased serum
albumin in many hypoalbuminemic patients. Since purified
human albumin preparations are very expensive and their
sources are highly limitçd, the minimal use of albumin as a
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biovehicle for a diuretic as designed in the present study should
be strongly recommended for correcting the retention of extra-
cellular fluids and improving the relevant complications in these
patients. The present study may also open the possibility that
many other drugs that bind strongly to albumin could excert
their pharmacological actions in a combined use of albumin as
a biovehicle protein in hypoalbuminemic human subjects.
Reprint requests to Dr. M. Inoue, Department of Biochemistry,
Kumamoto University Medical School, 2-2-I, Honjo, Kumamoto 860,
Japan.
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